1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Original Article
Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study
Article first published online: 5 DEC 2005
DOI: 10.1002/hep.1840130403
Copyright © 1991 American Association for the Study of Liver Diseases
1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
Additional Information
How to Cite
Liaw, Y.-F., Sheen, I.-S., Chen, T.-J., Chu, C.-M. and Pao, C.-C. (1991), Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology, 13: 627–631. doi: 10.1002/hep.1840130403
Publication History
- Issue published online: 5 DEC 2005
- Article first published online: 5 DEC 2005
- Manuscript Accepted: 10 OCT 1990
- Manuscript Received: 10 MAY 1990
Funded by
- National Science Council, R.O.C.. Grant Numbers: NSC-77-0610-B-182-04, NSC-78-0419-B-182-03
- Prosperous Foundation, Taipei, Taiwan
- Abstract
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without, Digestive Diseases and Sciences, 2013, 58, 1, 275
- 2, , Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog, Journal of Gastroenterology, 2013, 48, 1, 13
- 3, , Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen, Tzu Chi Medical Journal, 2013, 25, 2, 75
- 4, , , , , , , , , , , , , , , , , Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis, Liver International, 2012, 32, 4Direct Link:
- 5, , , , Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada, Value in Health, 2012, 15, 6, 894
- 6, , , , , , , Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making, Value in Health Regional Issues, 2012, 1, 1, 7
- 7, , , , Decreasing Levels of HBsAg Predict HBsAg Seroclearance in Patients With Inactive Chronic Hepatitis B Virus Infection, Clinical Gastroenterology and Hepatology, 2012, 10, 3, 297
- 8, , , , , , , , , , , Determinants of spontaneous surface antigen loss in hepatitis B e antigen–negative patients with a low viral load, Hepatology, 2012, 55, 1Direct Link:
- 9, , , , , , , , Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients, Journal of Viral Hepatitis, 2012, 19, 3Direct Link:
- 10KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109
- 11, Quantification de l’AgHBs : nouvel outil virologique pour la prise en charge de l’hépatite B chronique, Revue Francophone des Laboratoires, 2012, 2012, 447, 33
- 12, , , , , , , , , , , , Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients, The Korean Journal of Hepatology, 2011, 17, 3, 206
- 13, , Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection, PharmacoEconomics, 2011, 29, 12, 1063
- 14, , , , , , , , , , , , , , HBsAg Seroclearance in Chronic Hepatitis B, Journal of Clinical Gastroenterology, 2011, 45, 1, 64
- 15, , , , , , , , Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients, Digestion, 2011, 84, s1, 23
- 16, , , , , , , , Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters, Gastroenterology, 2011, 141, 2, 517
- 17, , , Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B, Hepatology, 2010, 51, 2Direct Link:
- 18, , Chronic Hepatitis B: Past, Present, and Future, Clinics in Liver Disease, 2010, 14, 3, 531
- 19, , , , , , , , Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus, Hepatology, 2010, 51, 5Direct Link:
- 20, , , Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 6, 717
- 21, , , , , Implications of the relationship between maternal age and parity with hepatitis B carrier status in a high endemicity area, Journal of Viral Hepatitis, 2010, 17, 5Direct Link:
- 22, , , , , , , , , Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study, Gastroenterology, 2010, 139, 2, 474
- 23, , , , , , , , , Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients, Hepatology, 2010, 52, 5Direct Link:
- 24, , , , , , , , , Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B, Journal of Viral Hepatitis, 2010, 17, 1Direct Link:
- 25, , Négativation de l’antigène HBs : valeur pronostique pour la réponse au traitement et l’évolution à long terme, Gastroentérologie Clinique et Biologique, 2010, 34, S119
- 26
- 27, Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia, Journal of Hepatology, 2009, 51, 2, 403
- 28, Clinical outcomes and development of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients, The Korean Journal of Hepatology, 2009, 15, 3, 383
- 29, , , , Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen, Clinical Gastroenterology and Hepatology, 2009, 7, 8, 889
- 30, , , Evaluation of the patient with hepatitis B, Hepatology, 2009, 49, S5Direct Link:
- 31, , HBsAg Seroclearance: The More and Earlier, the Better, Gastroenterology, 2009, 136, 5, 1842
- 32
- 33, , Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence, Vaccine, 2009, 27, 48, 6770
- 34, The natural history of chronic hepatitis B virus infection, Hepatology, 2009, 49, S5Direct Link:
- 35
- 36, , Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1031
- 37, , , , , , , , , HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma, Gastroenterology, 2008, 135, 4, 1192
- 38, , Historia natural y manifestaciones clínicas de la hepatitis B crónica, Enfermedades Infecciosas y Microbiología Clínica, 2008, 26, 11
- 39, , , , , , , The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis, Advances in Therapy, 2008, 25, 3, 190
- 40, , Chronic hepatitis B, Hepatology, 2007, 45, 2Direct Link:
- 41, , , , , , , , , , Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection, The Korean Journal of Internal Medicine, 2007, 22, 2, 73
- 42, , , , , , , , , , , , Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B, Journal of Medical Virology, 2007, 79, 9Direct Link:
- 43, , HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up, Hepatology, 2007, 45, 5Direct Link:
- 44, , , , , , , , , , Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea, Digestive Diseases and Sciences, 2007, 52, 9, 2403
- 45, , , Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study, Clinics in Liver Disease, 2007, 11, 4, 797
- 46, , , , Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study, Hepatology International, 2007, 1, 1, 267
- 47, , , Natural History of Hepatitis B Virus Infection: An Update for Clinicians, Mayo Clinic Proceedings, 2007, 82, 8, 967
- 48, , , Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma, Current Hepatitis Reports, 2007, 6, 1, 9
- 49, , , Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?, International Journal of Obesity, 2006,
- 50, , Hbsag seroclearance in the natural history of chronic hepatitis b infection, Current Hepatitis Reports, 2006, 5, 1, 23
- 51, , , , , , , , , , , , Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis B, The American Journal of Medicine, 2006, 119, 1, 71.e9
- 52, , , , , , , , , , Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance, Journal of Hepatology, 2005, 42, 2, 188
- 53, , , , , , , , , , , , , , , Possible contribution of prior hepatitis B virus infection to the development of hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2005, 20, 6Direct Link:
- 54
- 55, , Occult hepatitis B virus infection in patients with hepatocellular carcinoma: innocent bystander, cofactor, or culprit?, Gastroenterology, 2004, 126, 1, 347
- 56, Prevention of hepatitis B virus–related hepatocellular carcinoma, Gastroenterology, 2004, 127, 5, S303
- 57
- 58
- 59, EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B, Journal of Hepatology, 2003, 39, 3
- 60, , , , , , Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen, Journal of Gastroenterology and Hepatology, 2003, 18, 10Direct Link:
- 61
- 62, , Natural history of hepatitis b and outcomes after liver transplantation, Clinics in Liver Disease, 2003, 7, 3, 521
- 63, , , , , , , , , , Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen, Gastroenterology, 2002, 122, 3, 614
- 64, , Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?, Journal of Hepatology, 2000, 33, 2, 329
- 65
- 66, , , , , , , , Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen, Journal of Hepatology, 1998, 28, 6, 915
- 67, , , , , Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: comparison with branched DNA assay, Journal of Virological Methods, 1997, 65, 2, 219
- 68, New treatments for chronic viral hepatitis B and C, Baillière's Clinical Gastroenterology, 1996, 10, 2, 299
- 69, , , Pathogenic role of hepatitis B virus in hepatitis B surface antigen—negative decompensated cirrhosis, Hepatology, 1995, 22, 1Direct Link:
- 70, Role of hepatitis C virus in dual and triple hepatitis virus infection, Hepatology, 1995, 22, 4Direct Link:
- 71, Rolling review–the pathogenesis, diagnosis and management of viral hepatitis, Alimentary Pharmacology & Therapeutics, 1994, 8, 2Direct Link:
- 72, , , , , , Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection, Hepatology, 1992, 15, 3Direct Link: